ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY

VOLUME 36, 1996

ARTHUR K. CHO, *Editor*
University of California School of Medicine, Los Angeles

TERRENCE F. BLASCHKE, *Associate Editor*
Stanford University Medical Center, Stanford

ING K. HO, *Associate Editor*
University of Mississippi Medical Center, Jackson

HORACE H. LOH, *Associate Editor*
University of Minnesota Medical School, Minneapolis

http://annurev.org science@annurev.org 415-493-4400

ANNUAL REVIEW INC. 4139 EL CAMINO WAY P.O. BOX 10139 PALO ALTO, CALIFORNIA 94303-0139

ANNUAL REVIEWS INC.
Palo Alto, California, USA

COPYRIGHT © 1996 BY ANNUAL REVIEWS INC., PALO ALTO, CALIFORNIA, USA. ALL RIGHTS RESERVED. The appearance of the code at the bottom of the first page of an article in this serial indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee of $8.00 per article through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923) for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. The per-copy fee of $8.00 per article also applies to the copying, under the stated conditions, of articles published in any Annual Review serial before January 1, 1978. Individual readers, and nonprofit libraries acting for them, are permitted to make a single copy of an article without charge for use in research or teaching. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. For such uses, written permission is required. Write to Permissions Dept., Annual Reviews Inc., 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139 USA.

International Standard Serial Number: 0362-1642
International Standard Book Number: 0–8243–0436-5
Library of Congress Catalog Card Number: 61-5649

Annual Review and publication titles are registered trademarks of Annual Reviews Inc.

♾ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Annual Reviews Inc. and the Editors of its publications assume no responsibility for the statements expressed by the contributors to this *Review*.

Typesetting by Kachina Typesetting Inc., Tempe, Arizona; John Olson, President; Toni Starr, Typesetting Coordinator; and by the Annual Reviews Inc. Editorial Staff

PRINTED AND BOUND IN THE UNITED STATES OF AMERICA

Annual Review of Pharmacology Toxicology
Volume 36 (1996)

CONTENTS

A PERSONAL VIEW OF PHARMACOLOGY, *James Black* 1

A CAREER IN TOXICOLOGY, *Robert A. Neal* 35

ANTIPROGESTINS: Mechanism of Action and Contraceptive Potential, *Irving M. Spitz, Horacio B. Croxatto, and Ann Robbins* 47

OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES, *N. A. Simonian and J. T. Coyle* 83

PROGRESS IN ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS, *Stanley T. Crooke and C. Frank Bennett* 107

MOLECULAR MECHANISMS OF TOXICANT-INDUCED IMMUNOSUPPRESSION: Role of Second Messengers, *M. P. Holsapple, J. G. Karras, J. A. Ledbetter, G. L. Schieven, S. W. Burchiel, D. R. Davila, A. R. Schatz, and N. E. Kaminski* 131

P-GLYCOPROTEINS AND MULTIDRUG RESISTANCE, *William T. Bellamy* 161

LIPID VS PROTEIN THEORIES OF ALCOHOL ACTION IN THE NERVOUS SYSTEM, *Robert W. Peoples, Chaoying Li, and Forrest F. Weight* 185

MOLECULAR MECHANISMS OF ESTROGEN CARCINOGENESIS, *J. D. Yager and J. G. Liehr* 203

CARDIAC ACTIONS OF ANTIHISTAMINES, *Raymond L. Woosley* 233

NEW PHARMACOLOGICAL STRATEGIES FOR PAIN RELIEF, *A. Dray and L. Urban* 253

ANGIOTENSIN RECEPTORS AND THEIR THERAPEUTIC IMPLICATIONS, *Kathy K. Griendling, Bernard Lassègue, and R. Wayne Alexander* 281

ASSESSMENT OF FOLLICLE DESTRUCTION IN CHEMICAL-INDUCED OVARIAN TOXICITY, *Patricia B. Hoyer and I. Glenn Sipes* 307

CNS EFFECTS AND ABUSE LIABILITY OF ANABOLIC-ANDROGENIC STEROIDS, *Scott E. Lukas* 333

PATHOPHYSIOLOGICAL BASIS OF VULNERABILITY TO DRUG ABUSE: Role of an Interaction Between Stress, Glucocorticoids, and Dopaminergic Neurons, *Pier Vincenzo Piazza and Michel Le Moal* 359

OPIOID RECEPTOR TYPES AND SUBTYPES: The δ Receptor as a Model, *Paulette A. Zaki, Edward J. Bilsky, Todd W. Vanderah, Josephine Lai, Christopher J. Evans, and Frank Porreca* 379

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES AND VASCULAR SMOOTH MUSCLE, *James B. Polson and Samuel J. Strada* 403

Diversity and Selectivity of Receptor–G Protein Interaction, *Thomas Gudermann, Frank Kalkbrenner, and Günter Schultz* 429

Complexity and Diversity of Mammalian Adenylyl Cyclases, *Roger K. Sunahara, Carmen W. Dessauer, and Alfred G. Gilman* 461

Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins, *J. H. Exton* 481

Imidazoline Receptors and Their Endogenous Ligands, *S. Regunathan and D. J. Reis* 511

Structural Mechanisms of HIV Drug Resistance, *John W. Erickson and Stanley K. Burt* 545

Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings, *Mary S. Wolff, Gwen Collman, J. Carl Barrett, and James Huff* 573

Pharmacology of Nicotine: Addiction and Therapeutics, *Neal L. Benowitz* 597

Insulin Signal Transduction and the IRS Proteins, *Martin G. Myers, Jr. and Morris F. White* 615

Exocytosis: Proteins and Perturbations, *George J. Augustine, Marie E. Burns, William M. DeBello, Diana L. Pettit, Felix E. Schweizer* 659

INDEXES

Subject Index 703

Cumulative Index of Contributing Authors, Volumes 32–36 713

Cumulative Index of Titles, Volumes 32–36 715

SUBJECT INDEX

A

Aβ toxicity
  oxidative stress and, 97–98
Abortifascients
  antiprogestins as, 53–54
Acetylcholine, 5, 15
Actinomycin D, 162
Acyclovir, 566
Addiction
  drug-centered approach to, 359–61
  individual-centered approach to, 359–73
    dopaminergic neurons and, 367–73
    environment, 360–61
    glucocorticoids and, 365–73
    novelty, 361
    stress, 359–61, 263–65, 368–72
    vulnerability, 361–73
  nicotine, 597, 600–2
    delivery system and, 601–2
    self-administration, 601
Adenosine
  NECA and, 27–29
Adenylcyclases, 461–76
  calmodulin and, 462, 466, 469–76
  forskolin and, 462
  isoforms of, 463–65, 473, 475–76
    location, 463–64
  structural features, 465–67
Adrenergic receptor ligands
  analgesia and, 271
Adrenoreceptors, 2, 8, 18–20
  α, 18–20
    heterogeneity of, 18–20
  β, 2, 8, 18–19
Advanced glycation end products (AGEs), 98
Aggression
  anabolic-androgenic steroids and, 333, 339–40, 345–52
  exposure to
    drug abuse vulnerability and, 363–65
Aging
  I_1 imidazoline expression and, 522
  oxidative stress and, 87
Agmatine, 531–36
  biological actions, 533–34
  distribution, 531–33
  isolation, 531
Agonist, 2–29
  dose-response curves, 3–9
  partial, 2–3
Ah receptor, 147–48, 153
AIDS
  antiviral therapy, 545–67
  drug-resistant variants, 545–67
AIDS research
  HIV virus inhibitors
    protease (PR), 545–46, 556–64
    reverse transcriptase (RT), 545–46
Alcohol
  effect on CNS of, 185–97
    cut-off effects, 191–93
    membrane lipid composition and, 191
    membrane lipid theory of, 185–89
    neurotransmitter-gated ion channels and, 189–91, 193–97
    pressure reversal, 190–91
    protein theory of action of, 185, 189–90
    stereoselectivity, 190
  self-administration of saccharin solution intake and, 363
Alzheimer's disease, 83, 97–98, 522, 597, 607–8
  advanced glycation end products and, 98
  I_2 expression and, 522
  oxidative damage in brains of patients with, 98
  nicotine therapy for, 597, 607–8
  oxidative stress and, 97–98
    Aβ toxicity and, 97–98
    polymerization of tau and, 97–98
AMPA receptor–ion channels
  effects of alcohol on, 196
Amphetamine
  self-administration of, 362–66
    glucocorticoids and, 366
    prenatal stress and, 364
    stress and, 363–65
    sugar intake and, 363
Amytrophic lateral sclerosis (ALS), 83, 95–96
  familial, 95–96
  gain in function in, 95
  oxidative cellular damage in, 95–96
  SOD-1 mutations in, 95–96
Anabolic-androgenic steroids
  testosterone, 333–52
    abuse liability, 333–46
    adolescent boys' use of, 340–41
    aggression and, 333, 339–40, 345–47
    17α-alkylated derivatives of, 334
    athlete abusers, 334, 337–40
    black market for, 341
    dependence potential of, 335–39
    17β-esterfied derivatives of, 334
    harm reduction approach to use of, 341
    legitamate medical uses of, 334
    modified ring structured analogues of, 334
    neuroactive steroids and, 347–50, 352
    nonathlete abusers of, 340
Analgesia, 253–72
  adrenergic receptor ligands, 271
  central nervous system, 255, 265–71
    facilatory neuropeptides and, 265–68
    inhibitory neuropeptides and, 268
  excitatory amino acids, 255, 269–70
  metabotropic glutamate receptors, 270
  peripheral nervous system, 255–64
    cytokine inhibition, 257
    eicosanoid inhibitors,255–57
    kinin antagonists, 258–59
    membrane ion channels, 260–62
    NGF, 259–60
    opioids, 253, 264
    vanilloids, 262–64
  purines, 270–71
Analytical pharmacology, 29–31
Angiotensin, 440
Angiotensin II, 281–300
  AT_1 receptors, 282–93, 297–300
  AT_2 receptors, 293–96
  hypertension and, 281–82, 298

myocardial infarction and, 281, 299–300
receptor agonists
potential therapeutic applications, 297–300
Angiotensin-converting enzyme inhibitors, 298–300
Antagonist, 2–29
indirect competitive, 11–14
Antihistamines
nonsedating, 233–49
arrhythmias caused by, 233–40
prolongation of QT interval by, 235–37
Antihypertensives, 511–36
clonidine, 511–36
I_1 receptors and, 517–18
idazoxan, 512, 514
Antioxidant response elements, 134
Antioxidants, 84–85
Antiprogestins, 47–73
antiglucocorticoid properties, 47
chemistry, 48–50
clinical applications, 53–56
contraceptive potential, 56–73
antifolliculotropic effect, 56–62
continuous administration, 62–65, 67
endometrial development and, 65–70
estrogenic or antiestrogenic effect on endometrium, 63–64
intermittent administration, 62
luteinizing hormone inhibition, 56–62, 65
postcoital administration, 72–73
progestin and, 65
lilopristone, 48–50, 57
mechanism of action, 50–53
mifepristone, 47
onapristone, 47–51, 57, 65
potential therapeutic uses, 47–50, 57
Antisense oligonucleotides, 107–21
affinity to receptor sequences hybridization interactions and, 108–9
cytokine release by, 117
in vitro cellular uptake, 111–12
in vivo parenteral pharmacokinetics, 112–15
interactions with proteins, 113–15
mechanism of action, 109
metabolic pathway of, 111
methylphosphonate, 119–20
phosphorothioate class of, 110–18
toxicities of, 117–18
Antisense techniques
G-protein functions detected through, 444–46
Antiviral therapy
drug-resistant HIV, 545–67
methods to combat, 564–67
Apoptosis, 133, 136, 143, 152
oxidative stress and, 136
Arachidonic acid, 92–93, 255
metabolism
free radical formation and, 92–93
xanthine oxidase and, 92–93
Arrhythmia
nonsedating antihistamines and, 233–49
astemizole, 233–34
clinical drug interactions, 240–42, 246–48
potassium channel block and, 235–37, 239, 244
terfenadine, 233–34, 237–42, 246–48
Arthritis
nicotine and, 604
Aryl hydrocarbon (AH) receptor protein
TCDD and, 39–40
Astemizole
cardiac arrhythmias and, 233–34, 242–44
potassium channel block by, 244
ATP-binding cassette (ABC) superfamily, 168
ATP receptor–ion channels
effects of alcohols on, 195
AT receptors (See Angiotensin)
Atresia, 308–9
Attention deficit disorder
nicotine therapy for, 597, 607, 609

B

Bleomycin, 170
Bosentan, 268
Bradykinin, 258, 266
Breast cancer, 203, 206–9, 220–22, 573–91
chemical and environmental exposures and, 573–91
alcohol intake, 584, 587, 590
ionizing radiation, 573, 575–77, 587, 590
organochlorine, 577–80
polycyclic aromatic hydrocarbons, 580–81
prenatal, 574
reproductive hormone, 203, 206–9, 220–22, 573, 585–87
smoking, 580–81
time of life of, 573–77, 583–84
workplace, 581, 583

C

Calcitonin gene–related peptide, 260
Calcium
exocytosis and, 659–90
inositol trisphosphate and regulation of cellular, 481–83
Calcium-calmodulin-dependent protein kinase, 670–71
Calcium-dependent proteases, 132
Calcium signaling
disruption by toxic substances, 132–33, 143–46
polycyclic aromatic hydrocarbons, 143–46
TCDD-induced suppression of B-cell function and, 46–53
Calmodulin, 405–6, 484, 462, 466, 469–76
adenylyl cyclase activation and, 462, 466, 469–76
MARCKS protein and, 484
Calmodulin-dependent kinase II, 132
Calpain, 94–95
Cancer
breast, 203, 206–9, 220–22, 573–91
endometrial, 203
estrogen and, 203–22
DNA damage from metabolites of, 209–12
multidrug resistance and, 161–77
ovarian, 203
(See also Breast cancer, Carcinogenesis, Chemotherapy, Multidrug Resistance)
Cannabinoids, 133–42
adenylate cyclase suppression and, 136–42
immunosuppression and, 133, 136–42
receptor expression, 141–42
distribution on specific cell types, 141–42
Capsaicin, 262–64
Carbon disulfide
cytochrome P450-catalyzed metabolism of, 38

Carcinogenesis
  catechol metabolites and, 206–9
  chemical
    breast cancer and, 203, 206–9, 220–22, 573, 577–91
  estrogen-induced, 203–22
    kidney and, 217–22
    liver and, 203, 213–17, 220–22
  exposure
    chemical, 573, 577–91
    prenatal, 574
    time of life of, 573–74, 576, 583–84
  hormonal, 204–22, 573, 585–87
  (See also Breast cancer, Cancer)
Cardiac hypertrophy, 299
Cardiovascular system
  nicotine and, 602–5
Catalase, 84
Catecholestrogens (4-OH-E2), 207–12
  estrogenicity, 208
  oxidative stress and damage from, 208–9
  TCDD and, 206
Catechol *O*-methyltransferase (COMT)
  tumorigenesis and, 212, 219–20
Cationic lipids, 111–12
Cell death
  mitochondrial energy failure and, 90
    excitotoxicity and, 90
Ceruloplasmin, 84–85
Cetirizine, 237, 244
Chemosensitization, 172–74
Chemotherapy
  multidrug resistance and, 161–77
    drugs involved in, 162
    high-dose, 170–71
    non–cross-resistant, 170
  ovarian failure and, 311–12
  overcoming, 170–77
Chlorodinitrobenzene (CDNB), 135
Cholecystokinin, 23
Cholinergic nervous system
  nicotine and, 597–98
Cilazapril, 299
Cimedine, 512, 519
Clonidine, 511–36
  ^{3}H-para-aminoclonidine analogue, 512
  hypotensive actions of
    I_1 imidazoline receptors and, 517–18
Clonidine-displacing substance, 511, 528–36
  classic, 528–30
  immunoreactive, 528, 530–31
Cocaine
  anabolic-androgenic steroid interactions with, 343–44, 345–47
    aggression and, 345–47
  estradiol protection from toxicity from, 343
  relapse in abuse of glucocorticoids and, 366
  self-administration of, 362–63
Contraceptives
  antiprogestins as potential, 56–73
    addition of progestin, 65
    antifolliculotropic effect, 56–62
    continuous administration, 62–65, 67
    endometrial development, 65–70
    estrogenic or antiestrogenic effect on endometrium, 63–65
    intermittent administration, 62
    luteinizing hormone inhibition, 56–62, 65
    postcoital administration, 72–73
  oral, 204, 213–22
Corticosterone
  drug abuse vulnerability and, 365–73
  reinforcing effects of, 366–67
  stimulation of dopamine release, 370
  stress-induced secretion of
    drug vulnerability and, 369–73
Cotinine
  nicotine metabolism and, 597, 600
Cushing syndrome
  mifespristone treatment of, 55
Cyclic AMP responsive element (CRE), 175
Cyclic nucleotide phosphodiesterases (PDEs), 403–23
  inhibitors, 406, 408–23
  isozymes
    calmodulin-dependent, 405–6
    cAMP-specific, 408
    cGMP-inhibited, 407
    cGMP-specific, 408
    cGMP-stimulated, 407
Cyclo-oxygenase, 256
Cyclophosphamide
  ovarian failure and, 312–13
Cyclosporin A, 172–73
Cyproheptadine, 235
Cysteine-string proteins, 668
Cytochrome P450, 204, 217, 233, 237, 247
Cytochrome P450-catalyzed metabolism, 37–39
  of carbon disulphide, 38
  of parathion, 37–38
  of thioadetamide, 38–39

D

DATATOP study, 97
Daunorubicin, 167
DDT
  breast cancer and, 577–80, 588–89
Decarbazine, 170
Denbufylline, 414
Depression
  I_1 imadazoline expression and, 518–19
Desoxycorticosterone (DOC), 347–48
Dexamethasone, 369
Diabetes mellitus
  insulin-dependent (IDDM), 616–17
  mature-onset diabetes in the young (MODY), 617
  non–insulin-dependent (NIDDM), 616–17
Diacylglycerol (DAG), 135, 482–84
  protein kinase C regulation and, 483–84
1,2-Dibromo-3-chloropropane (DBCP)
  breast cancer and, 588
Dichloro-analogues of isoprenaline (DCI), 2–3
bis-(4-chlorophenyl)-1,1-Dichloroethene (DDE)
  breast cancer and, 577–80
Diepoxide, 318–19
  ovarian toxicity and, 318
Diethylstilbesterol (DES), 204, 209, 213–20, 585–88, 590–91
  breast cancer and, 584–85, 587–88, 590–91
  hepatocarcinogenesis and, 213–17
  metabolic redox cycling of, 209
  oxidative stress and damage from, 208–9
Dihydroxyphenylacetic acid (DOPAC), 367
Diphenhydramine, 245
DMSO, 164
DNA
  antisense oligonucleotide therapeutics and, 107–21

modifications of oligonucleotide structure and, 118–20
hybridization of phosphorothioate oligonucleotides to, 110, 118
oxidative damage from estrogen metabolites, 204, 206–20
DOC2, 670
Dopaminergic neurons
vulnerability to drug abuse and, 359, 367–73
interactions with glucocorticoids and stress and, 368–73
Dose-reponse, 43–44
Doxorubicin, 169, 170, 173
Dreprenyl
delays in parkinsonian disability from, 97
Drug abuse
anabolic-androgenic steroids, 333–52
athlete abusers, 334, 337–40
endocrine system and, 342–43
liability for, 335–40
methods for assessing, 336–39
nonathlete abusers, 340
vulnerability to, 361–73
corticosterone and, 365–67
dopaminergic neurons and, 359, 367–73
environment, 360–61
glucocorticoids and, 365–72
novelty, 361
stress, 359–61, 363–65, 368–72
Drug dependence
potential for, 335–39, 352
anabolic-androgenic steroids and, 335–39
assessment of, 336
defined, 335
Drug resistance
herpes, 566
HIV, 545–67
influenza, 566
rhinovirus, 566

E

Eicosanoid
inhibition of inflammation, 255–57
Electromagnetic field (EMF) radiation
breast cancer and, 573, 576–77
melatonin and, 577
Endocrine system
nicotine and, 602–5
Endometrium, 47, 53–56
antiprogestin's effect on, 53–56
Epidermal growth factor, 484, 617
Erythromycin, 241, 246–48
Estradiol, 47, 61, 63, 66, 204–6, 213–17, 343
drug toxicity and, 343
enhanced dopamine receptor sensitivity from, 343
pathways for oxidative metabolism of, 204–6
Estrogen
breast cancer and, 573, 585–87
carcinogenesis, 203–22
inhibition of aggressive behavior by, 350
metabolic oxidations of, 204–9
metabolites, 206–20
catechol, 207–9
detoxification of, 212
DNA damage from, 209–20
estrogenicity, 208–9
16α-hydroxyesterone, 204, 206–7
mutagenicity of, 211–12
protein binding, 211
Estrogen carcinogenesis, 203–22
kidney, 217–22
liver, 203, 213–17, 220–22
mammary, 203, 206–9, 220–22
Estrone (E1)
16α-hydroxy-, 204, 206–7
pathways for oxidative metabolism of, 204–6
Ethanol
interactions with anabolic-androgenic steroids, 343–52
aggressive behavior and, 345–52
17α-Ethinyl estradiol (EE), 213–17
Ethylene dibromide
breast cancer and, 588
Ethylene oxide
breast cancer and, 588
Etoposide (VP-16), 162
Excitotoxicity
oxidative stress and, 88–91
Exocytosis, 659–90
calcium triggering and, 680–83
possible model for, 686–90
priming and, 678–80
proteins involved in
cytoplasmic, 673–75
perturbation methods, 660–67
plasma-membrane, 671–73
study methods, 660–67
vesicle-associated, 667–71
vesicle docking and, 675–78
vesicle fusion and, 678–90

F

Follicles
atresia, 308–9
chemicals that damage ovarian, 309–10, 315–26
development of, 308–9
follicular metabolism, 320–21
primordial, 308–25
destruction of oocytes in, 310–25
Follicle stimulating hormone (FSH), 62, 431, 439
Forskolin, 40, 462, 467–68
adenylyl cyclase activation by, 462, 467
Free radicals, 83–85, 89–95
arachidonic acid metabolism and, 92–93
cellular defense systems against, 84–85
glutamate receptor–linked processes and, 88–89
intracellular pathways involved in generation of, 89–95
mitochondrial electron transport chain and, 89–91
cell death and, 90
nitric oxide, 83–84, 91–92
protease activation and, 93–95

G

G protein–coupled receptors, 137–42, 379–96, 429–48
cannabinoid receptors, 137–42
convergent signaling, 437–38
divergent signaling, 438–42
mutations in, 345–47
nonautoimmune autosomal dominant hyperthyroidism and, 343
toxic hyperthyroid adenomas and, 343
opioid receptor, 379–96
selectivity of receptor–G protein coupling, 442–46
antisense techniques and, 444–46
signal sorting by, 431–37
alternatively spliced receptors and, 431, 433
multiple activated states of, 435
receptor conformation and, 433, 435–37
receptor subtypes and, 431
G protein–regulated pathways, 132, 136–42
disruption by toxic substances, 132

immunosuppression and, cannabinoids and, 133
G proteins
convergent coupling of receptors to, 437–38
coupling to effectors and receptors by
domains involved in, 493–95
regulation of phosphoinositide phospholipase C by, 486–501
βγ subunits and, 497–500
specificity of G-protein interaction with receptors, 500
stimulation of adenylyl cyclases by, 461–62, 467–71, 473–76
G_i receptors, 481, 490–91
calcium mobilizing receptors and, 490–91
receptor domains involved in coupling to, 491–93
G_q receptors, 481, 487–90
activation of phosphoinositide phospholipases by α-subunits of, 495–96
Ca^{2+} mobilizing receptors and, 488–90
receptor domains involved in coupling to, 491–93
$GABA_A$ receptor–ion channels
effects of alcohol on, 194
Gaddum-Schild model of competitive antagonism, 4
Galanin, 628
Ganciclovir, 566
Gastrin, 12–16
GEM91, 117
Glucagon-like peptide, 439
Glucocorticoid responsive element, 175
Glucocorticoids
drug vulnerability and, 359, 365–73
interaction with dopamine and stress, 368–73
Glucose transport
insulin and, 615–17, 644–46
IRS proteins and, 644–46
Glucosteroid receptors
mifepristone (RU 486) and, 47
Glutamate receptors, 88–93, 270
free radical production and, 88–93
arachidonic acid metabolism and, 92–93
excitotoxicity and, 88–91
metabotropic
analgesia and, 270
Glutathione, 84
GRB-2, 639
Growth factors
nociception and, 253, 255, 257, 259–60, 266
Growth hormone–releasing hormone (GHRH), 433
Guanabenz, 514–15
Guanidino-analogue of histamine (IEG)
partial agonist actions of, 3
Guanine nucleotide binding proteins (See G proteins)
Guanine nucleotide exchange factor (GEF), 447
Guanylyl cyclase, 415–16

H

^{3}H-idazoxan (See Idazoxan)
Halogenated aromatic hydrocarbons, 146
Heart failure
angiotensin-converting enzyme inhibitors and, 281, 300
Heme-oxygenase, 85
Hepatocarcinogenesis
estrogen-induced, 203, 213–17, 220–22
Heptahelical proteins, 491–93
Heptahelical receptors, 446–48
Herbimycin A, 135
Hexestrol, 218
Histamine
cimetidine and
interaction between, 4
gastrin and, 12–14
HIV
drug-resistant variants, 545–67
protease inhibitors (PR), 545–46, 556–64
reverse transcriptase (RT) inhibitors, 545–56
16α-Hydroxyesterone (16αOH-E1), 204, 206–7, 222
increased risk of breast cancer from, 206–7
5-HT_3 receptor ion channels
effects of alcohol on, 196
Hydroxyzine, 235, 244–45
Hyperbolic Hill equation, 6
Hypertension
angiotensin II and, 281–82, 298
immunoreactive clonidine-displacing substance and, 531
(See also Antihypertensives)
Hyperthyroid adenomas
toxic
mutations in G protein–coupled receptors and, 435
Hyperthyroidism
nonautoimmune autosomal dominant mutations in G protein–coupled receptors and, 435
Hypothalamus
ovarian function and, 308–9
ovarian toxicity and, 309, 311

I

Idazoxan, 512, 514
Imidazoline receptor binding protein (IRBP), 526–28
Imidazoline receptor binding protein–like immunoreactivity, 526–28
Imidazoline receptors, 511–36
disease, 518–19, 522
functions, 517–18, 521–22
non-I_1, non-I_2, 522–23
pharmacology, 514–20
receptor protein localization, 526–28
signal transduction, 516, 520–21
structure, 523–26
subcellular distribution, 516, 520
Immune regulation
second messengers' role in, 132–33
Immunosuppression, 131–54
cannabis and, 133–42
oxidative stress and, 133–36
polyaromatic hydrocarbons and, 133, 143–46
second messengers and, 131–54
TCDD, 133, 146–53
Immunotoxicity
cannabinoid receptors and, 137–42
TCDD-induced, 146–53
Infertility
ovarian toxicity and, 309–26
Inflammation
inhibition of
cytokine, 257
eicosanoid, 255–57
ion channel function in
changes in, 260–62
Inositol 1,4,5-trisphosphate (IP_3), 135, 481–83
calcium regulation and, 481–83
Insulin
binding, 617–19
control of protein synthesis by, 646–47
metabolism and
glucose disposal and, 615–17
Insulin receptor
structure, 617
substrates, 621–48
insulin receptor substrate-1 (IRS-1), 621–32, 642–48

phosphotyrosine-containing protein (PP185), 621
ppl2O, 621–22
Vav, 622
tyrosine kinase activation and autophosphorylation and, 617–20
Insulin signal transduction
GRB-2 and, 639–40
insulin receptor substrate (IRS) proteins and, 621–32, 642–48
phosphatidyl inositol 3-kinase and, 634–39
SH2 domains and, 622, 632–41
SHPTP2 and, 640–41
tyrosine kinase and, 617–48
tyrosine phosphorylation sites in IRS proteins, 625, 628
Interleukin, 257
Interleukin-1β–converting enzyme (ICE), 93–94
Interleukin-2 (IL-2), 133
Ionizing radiation
breast cancer and, 573, 575–77
ovarian failure and, 312
ISIS 2105, 2302, 2922, 117
Ivermectin, 164

J

Janus kinase, 448

K

Kainate receptor-ion channels
effects of alcohol on, 196
Ketoconazole, 246–48
Kidney carcinogensis
estrogen-induced, 203, 217–30
Kinins, 253, 258–59, 265–68
antagonists, 258–59
neuro-, 265–68

L

Langendorff preparation, 2
Leukotriene B_4, 257
Lilopristone, 48–50, 57
Lipid peroxidation, 85
Loratidine, 237, 244
Losartan, 297–300
Lung cancer resistance protein, 56, 176
Luteinizing hormone (LH)
antiprogestins and inhibition of, 56–62, 65
Luteinizing hormone–chorionic gonadotropin (LH-CG), 431, 439

M

*MDR*1 gene, 162–77
expression of
normal, 168–69
tumor, 169–70
family, 163–65
modulation of, 170–74
potential transcriptional regulatory elements in human, 164
Mechlorethamine, 170
Melatonin
electromagnetic field radiation and, 577
Membrane fusion, 678–90
Membrane lipids
effect of alcohol on, 185–89, 191
mechanism of action of, 186–88
Menopause
ovarian toxicity and precocious ovarian failure, 310
Metabolism
nicotine's effects on, 604–5
Metallothionein, 85,
Metarhodopsin, 435–36
Methoxydozoxan, 517
Methylcholanthrene
breast cancer and, 589
Methylnitrosourea
breast cancer and, 589
Mifepristone (RU 486), 47–73
antiglucocorticoid properties, 47
chemistry, 48–50
clinical treatment applications, 53–56
contraceptive potential, 56–73
continuous administration, 62–65
endometrial development and, 65–70
estrogenic or antiestrogenic effect on endometrium, 63–64
intermittent administration dose-response effect, 62
postcoital administration, 72–73
weak progestin agonist, 64
Cushing syndrome treatment with, 55
Migraine, 266, 268
Mitochondria, 511
Mitochondrial oxidative metabolism
free radical formation and, 83–84
Mitogen-activated protein kinases (MAPKs), 132, 447
Mitoxantrone, 162
Morphine
self-administration of, 362, 366
glucocorticoids and, 366
Moxestrol, 218
Moxonidine, 514, 517–19
Multidrug resistance, 161–77
agents that reverse, 172
cellular alterations resulting from, 162
chemosensitization and, 172–74
chemotherapeutic drugs involved in, 162
genes for, 162–77
non–P-glycoprotein–mediated, 174–77
p53 role in, 165
P-glycoprotein expression and, 162, 165
phenotype, 162–63
Multidrug-resistance-related protein (MRP), 174–77
Myocardial infarction, 281, 299–300
Myoinositol 1,4,5-trisphosphate (IP_3), 482–83

N

Naloxone, 268
α-Naphthoflavone (ANF), 213–17
NECA
adenosine and, 27–29
Nerve growth factor (NGF)
analgesia and, 259–60, 266
nociception and, 259–60, 266
Neurofibrillary tangles
oxidative stress and, 98
Neurokinin, 265–68
Neurotransmitter-gated ion channels
effects of alcohols on, 189–91, 193–97
AMPA receptor, 196
ATP receptor, 195
GABA receptor, 194
5-HT_3 receptor, 196
kainate receptor, 196
nicotinic ACh receptor, 193–94
NMDA receptor, 195
Nicotine
addiction to, 597, 600–2
cardiovascular system and, 602–5
endocrine system and, 602–5
mechanisms of action of, 598–99
metabolic effects, 604–5
metabolism, 599–600
metabolites, 605
pharmacokinetics, 599–600

therapeutic uses
Alzheimer's disease, 597, 607–8
attention deficit disorder, 597, 607–9
nicotine replacement therapy, 605–7
Parkinson's disease, 597, 607–8
sleep apnea, 597, 607, 609
Tourette syndrome, 597, 607–9
Nicotinic ACh receptor
effects of alcohol on, 193–94
Nitric oxide, 83–84, 91–92
synaptic plasticity and, 91
synaptogenesis and, 91
toxicity and, 91–92
Nitric oxide synthase (NOS), 90–92
NMDA receptor ion channels
effects of alcohol on, 195
Nociception, 253–72
adrenergic receptor ligands and, 271
excitatory amino acids and, 255, 269–70
facilatory neuropeptides and, 265–68
inhibitory neuropeptides and, 269
metabotropic glutamate receptors and, 270
modulatory neuropeptides and, 269
neurokinins and, 265–68
purines and, 270–71
Nonsteroidal antiinflammatory drugs (NSAIDs), 254, 256–57
Noradrenaline
dualist behavior of, 25
Norethindrone, 49
Nucleosides (See Antisense oligonucleotides)

O

OL(1)p53, 117
Oligonucleotide analogues (See Antisense oligonucleotides)
Onapristone, 47–51, 57, 65
Oocytes, 307–25
destruction of
biomarkers for, 310–12
long-term effects of, 323–25
ovarian toxicity and, 309–26
Opioid analgesics, 253, 264
Opioid drugs, 362–65
stress and self-administration of, 362
Opioid receptor, 379–96
δ (DOR), 379–96
antisense oligodeoxynucleotide (ODN) studies, 389–92
genetic characteristics, 380–81
multiple subtypes, 384–89
structure, 381–84
κ (KOR), 379–80, 392–96
μ (MOR), 379–80, 392–96
Organochlorines
breast cancer and, 577–80
Osteoporosis
cigarette smoking and, 604
Ovarian function, 307–11
atresia and, 308–9
cyclicity and, 308, 311
follicular development and, 308–9
Ovarian toxicity, 307, 309–26
biomarkers for, 310–12
chemotherapy and, 312–13
follicle destruction, 309–10
ionizing radiation and, 312
mechanism of, 319–22
cell death and, 321
follicular metabolism and, 320–21
protein synthesis and, 321
target cells and, 322
ovotoxic chemicals, 309–10, 312–14
polycyclic aromatic hydrocarbons and, 313
precocious menopause and, 310
4-vinylcyclohexene-induced, 307, 315–26
bioactivation of, 316–17
detoxification, 318–19
Ovotoxicity (See Ovarian toxicity)
Oxidative DNA damage, 204, 206–9
catecholestrogens and, 208–9
16α-hydroxyestrone and, 204, 206–7
Oxidative stress, 83–99, 133–36
aging and, 87
Alzheimer's disease and, 97–98
amytrophic lateral sclerosis and, 95–96
apoptosis and, 87, 89, 136
DNA damage from, 87
excitotoxicity and, 88–91
glutamate receptor–linked processes and, 88–89
immunotoxicity and, 133–35
lipid peroxidation and, 85
necrosis and, 87–88
neurodegeneration and, 83–99
Parkinson's disease and, 96–97
reactive oxygen species and, 84–95
cellular defense systems against, 84–85

P

p21-activated kinases (PAKs), 448
p53
role in multidrug resistance, 165
Pain
chronic, 253–72
nociceptive, 253–55
relief of (See Analgesia)
signaling
changes in, 254–55
chronic pain disorders and, 255
Parathion, 37–38
Parathyroid hormone–parathyroid hormone related peptide (PTH-PTHP), 439
Parkinson's disease, 83, 90, 96–97, 597, 607–8
nicotine therapy for, 597, 607–8
oxidative stress and, 96–97
P-glycoproteins
ATPase activity with, 166–67
drug binding site on, 167
multidrug resistance due to, 161–77
high-dose chemotherapy and, 170–71
non–cross-resistant chemotherapy and, 170
overcoming, 170–74
protein- and gene-directed therapy and, 171
structure and function, 165
transport and binding, 166–68
Pharmacological models, 3–31
analytical pharmacology and, 29–31
pharmacological resultant and, 24–29
Pharmacological resultant, 24–29
Phentolamine, 514, 521, 523
Phenylethanolamine *N*-methyltransferase (PNMT), 518
Phenylethylamines, 512, 518
Phosphatidylinositol (PI), 622, 634–39
insulin signal transduction and, 634–39
Phosphatidylinositol 4,5-bisphosphate, 481–83, 487–501
Phosphoinositide-specific phospholipase C (PI-PLC), 481–501
G proteins regulating, 486–87
Phospholipase C_{gamma1}, 133–35

Phospholipid metabolism
formation of free radicals and, 83–84
Phosphorothioate oligodeoxynucleotides, 107, 110–18
cytokine release by, 117
hybridization to DNA and RNA, 110
interactions with proteins, 113–15
in vitro cellular uptake, 111–12
in vivo parenteral pharmacokinetics, 112–13
metabolic pathway, 111
Phosphorylation, 472
Pituitary
ovarian function and, 308–9
ovarian toxicity and, 309, 311
Pituitary adenylyl cyclase activating polypeptide (PACAP), 437, 439
Platelet-derived growth factor receptor, 617
Pokeweed mitogen, 151
Polychlorinated biphenyls (PCBs)
breast cancer and, 577–80, 590–91
Polycyclic aromatic hydrocarbons (PAHs)
breast cancer and, 580–81, 589
immunotoxicity caused by alterations in calcium homeostasis and, 133, 143–46
ovarian toxicity and, 310, 313
Potassium channels
cardiac
astemizole and, 244
nonsedating antihistamines and, 233, 235–37, 239
terfenadine and, 239
Prednisone, 170
Procarbazine, 170
Progesterone, 47–73, 308
antagonists, 51–52
functions before embryo implantation, 56
Prostacyclin, 256–57
Prostaglandins, 256–57
Protease activation
formation of free radicals and, 93–95
Protease inhibitors
HIV drug-resistant mutations, 545–46, 556–64
active site mutants, 558, 561–63
cleavage site mutants, 564
nonactive site mutants, 563–64
Protein kinase
A (PKA), 139, 447
C (PKC), 132–33, 481–84
diacylglycerol and regulation of, 483–84
C-α (PKC-α), 115, 117
Protein perturbation, 660–67
genetic approaches to, 661–63
nongenetic approaches to, 663–67
Proteins
cytoplasmic, 673–75
effect of alcohol on, 185, 189–90
exocytosis and, 675–86
calcium triggering and, 680–83
priming and, 678–80
vesicle docking and, 675–78
vesicle fusion and, 683–86
plasma membrane, 671–73
vesicle-associated, 667–71
Protein tyrosine kinase (PTK)–linked receptor
disruption by toxic substances, 132–36
Protein tyrosine phosphatases (PTPs), 136
Proteolysis
oxidative stress and, 87–89, 94
Pulmonary hypertension
cyclic nucleotide phosphodiesterases and, 404
Purines
analgesia and, 270

Q

Quinone, 84
Quinonoid metabolites, 209–10

R

RAB3, 669–70
Rabphillin 3a, 670
Radiation
ionizing, 573, 575–77, 587
nonionizing, 573
Reactive oxygen species (ROS), 84–95
cellular defense systems against, 84–85
DNA damage from, 87
proteolysis and, 87–89, 94
Receptor conformation, 433, 435–37
Receptor heterogeneity
opioid, 379–96
evidence for multiple subtypes, 384–89
possible mechanisms for, 392–96
Receptors, 2–29, 4–48, 50–53
distributin of
K_A estimation and, 9–11
glucosteroid, 47
progesterone, 48, 50–53
isoforms of, 52–53
steroid, 52
two-receptor systems, 17–24
Receptor tyrosine kinases (RTKs), 448
Renin angiotensin system, 281–300
Reserpine, 585, 587
Restenosis
cyclic nucleotide phosphodiesterase inhibitors to prevent, 419
Reverse transcriptase inhibitors, 545–56
drug-resistant HIV mutations, 545
nonnucleoside inhibitor form of (NNIs), 546–56
drug resistance to, 550–52
nucleoside analogues (NIs), 546, 552–56
Rhodopsin, 442–44
Rilmenidine, 517
RNA
antisense oligonucleotide therapeutics and, 108–21
hybridization of phosphorothioate oligonucleotides to, 110
Rolipram, 413–14
Rostral ventrolateral medulla (RVL), 512, 517–18
RU 486 (See Mifepristone)

S

Second messengers
immunosuppression from toxic substances and, 131–54
role in immune regulation, 132
Secretin, 439
Self-administration
anabolic-androgenic steroids and, 335–39, 350
drug-abuse vulnerability and, 361–73
aggression and, 363–65
amphetamine, 361
cocaine, 361
corticosterone, 365–72
dopaminergic neurons and, 359, 367–72
environment and, 360–61
nicotine, 601
morphine, 361
novelty and, 361
stress and, 359–61, 363–73
SERCAs, 145–46, 152
SH2 domains
insulin signal transduction and, 622, 632–41

Signal transduction
adenyl cyclases and, 461–76
disruption by toxic substances, 132–54
calcium signaling and, 132
G protein–regulated pathways and, 132, 136–42
oxidative stress and, 133–36
PTK-linked receptors and, 132–36
G protein–mediated, 429–48
heptahelical receptors and, 446–48
I_1 imidazoline receptors and, 514–19
I_2 imidazoline receptors and, 519–22
insulin, 615–48
(See also G protein–coupled receptors, Insulin signal transduction)
Signal transduction and activators of transcription (STAT) pathway, 448
Sleep apnea
nicotine therapy for, 597, 607, 609
Smoking
breast cancer and, 580–81
(See also Nicotine)
Smoking cessation
nicotine replacement therapy and, 597, 605–7
Sodium butyrate, 164
Somatostatin, 268
Sprague-Dawley rats, 207, 313
Steroids
neuroactive, 347–50
(See Anabolic-androgenic steroids, Estrogen, Progesterone)
Stress
drug abuse and, 359–73
aggression and, 362–65
environment and, 359–61
interaction with glucocorticoids and dopamine and, 368–73
novelty and, 361
prenatal, 364
vulnerability to, 363–65, 368–72
Stress-activated protein kinases, 134, 447
Superoxide dismutase (SOD), 84, 94–96
SOD-1 mutations
amytrophic lateral sclerosis and, 95–96
Synaptobrevins, 667–68
Synaptogamins, 668
Synaptophysins, 669
Synapsins, 671

T

Tau
polymerization of
oxidative stress and, 97–98
Taxol, 162
TCDD
antiestrogenic properties of, 579
aryl hydrocarbon (AH) receptor protein and, 39–40
immunotoxicity caused by, 133, 146–53
Ah receptor function and, 147–48, 153
alterations in calcium homeostasis and, 133
suppression of B-cell function and, 146–53
increased catecholestrogen formation and, 206
liver carcinogenesis and estrogens and, 213–17
Teniposide (VM-26), 162
Terfenadine, 233–34, 237–42
block of potassium channels by, 239
cardiac arrythmias and, 233, 237–42
drug interactions and, 240–42, 246–48
torsades de pointes, 233, 234–42
ketoconazole with, 246–48
Testosterone (See Anabolic-androgenic steroids, testosterone)
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (See TCDD)
Δ^9-Tetrahydrocannabinol, 137–42
Thiocetamide
cytochrome P450-catalyzed metabolism of, 38–39
Thiomides
cytochrome P40-catalyzed metabolism of, 38–39
Thyroid-releasing hormone (TRH), 433, 440–41, 445
Thyroid-stimulating hormone (TSH), 431, 435–35, 439, 441–42, 445
Thyrotropin-releasing hormone, 490
Tobacco
addiction to, 597
(See also Nicotine, Smoking, Smoking cessation)
Torsades de pointes
antihistamines and, 233, 235–37, 246–49
drug interactions with, 246–48
terfenadine, 233, 237, 246–49
Tourette's syndrome
nicotine therapy for, 597, 607, 609
Toxic exposures
disruption of signal transduction from
calcium signaling, 132–33, 143–46
G protein–regulated pathways, 132
immunosuppression by, 131–54
PTK-linked receptors, 132, 136–42
Toxicity
ovarian (See Ovarian toxicity)
Tumor necrosis factor, 257, 134
α, 134
Tyrosine phosphorylation
insulin binding and
activation by autophosphorylation and, 617–20
SH2 domains and, 622, 632–41
sites in IRS proteins, 625, 628

U

Ulcerative colitis
nicotine therapy for, 607–8
Uric acid, 85

V

Vanilloids, 262–64
Vascular disease
cyclic nucleotide phosphodiesterases and, 404
Vascular smooth muscle, 281–83, 288, 403–23
cyclic nucleotide phosphodiesterase
inhibitors, 406, 408–23
isozymes, 403–8, 419–20
Vasopressin, 440
Ventral tegmental area
drug self-administration and, 362–63
Ventricular arrhythmia
nonsedating antihistamines and, 233–49
Ventricular remodeling
angiotensin and, 281, 299–300
Verapamil, 172–73
Vibrio parahaemoyticus, 111
Vinblastine, 162, 164, 170
Vincristine, 162, 169, 170

Vinpocetine, 406, 408–9
Vinyl chloride
  breast cancer and, 588
4-Vinylcyclohexene (VCH)
  ovarian toxicity from, 307, 315–26
    bioactivation, 316–17
    cell death, 321–22
    detoxification, 318–19
    mechanism of, 319–22
    protein sysnthesis and, 321
    repeated exposure, 323
    transplacental exposure, 323
Vitamin E, 84

X

Xanthine oxidase, 92–95
Xenobiotic response elements, 147
Xenobiotics
  breast cancer and exposure to, 203–4

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 32–36

A

Alexander RW, 36:281–306
Amidon GL, 34:321–41
Angle CR, 33:409–33
Augustine GJ, 36:659–701

B

Barrett JC, 36:573–96
Bellamy WT, 36:161–83
Bellomo G, 32:449–70
Bennett CF, 36:107–29
Benowitz NL, 36:597–613
Bertolino M, 32:399–421
Bevan JA, 34:173–90
Bilsky EJ, 36:379–401
Black J, 36:1–33
Bowery NG, 33:109–47
Boyer JL, 35:541–79
Brater DC, 33:435–65
Bray TM, 34:91–115
Briving C, 35:277–305
Bunzow JR, 33:281–307
Burch RM, 32:511–36
Burchiel SW, 36:131–59
Burns ME, 36:659–701
Burt SK, 36:545–71

C

Caron MG, 32:167–83
Chan P-C, 34:41–67
Chang LW, 34:41–67
Chao AC, 35:257–76
Chaudhuri G, 35:165–94
Chen AY, 34:191–218
Chiu AT, 32:135–65
Civelli O, 33:281–307
Claghorn JL, 33:165–77
Clarkson TW, 33:545–71
Collman GW, 36:573–96
Cordell B, 34:69–89
Corey JL, 34:219–49
Cory-Slechta DA, 35:391–415
Coyle JT, 36:83–106
Cronstein BN, 35:449–62
Crooke ST, 32:329–76; 36:107–29
Croxatto HB, 36:47–81

D

Dahl AR, 33:383–407
Davila DR, 36:131–59
Davis B, 35:341–68
DeBello WM, 36:659–701
De Mey JGR, 35:501–39
de Montellano PRO, 32:89–107
Dessauer CW, 36:461–80
Dray A, 36:253–80

E

Eaton DL, 34:135–72
Edwards G, 33:597–637
Elion GB, 33:1–23
Emmerson KS, 34:91–115
Erickson JW, 36:545–71
Esbenshade TA, 34:117–33
Evans CJ, 36:379–401
Exton JH, 36:481–509

F

Fan A, 35:341–68
Farley JM, 32:67–88
Farmer SG, 32:511–36
Felten DL, 35:417–48
Fenselau C, 32:555–78
Fisher MH, 32:537–53
Fryxell D, 32:579–621
Fukuto JM, 35:165–94
Fung B-K, 33:201–41
Furchgott RF, 35:1–27

G

Gallagher EP, 34:135–72
Gardner P, 35:257–76
Gilman AG, 36:461–80
Gnegy ME, 33:45–70
Gonzalez FJ, 35:369–90
Grandy DK, 33:281–307
Griendling KK, 36:281–306
Gudermann T, 36:429–59

H

Halpert JR, 35:29–53
Hankinson O, 35:307–40
Harden TK, 35:541–79
Harman AW, 35:129–44
Henrion D, 34:173–90
Herblin WF, 32:135–65
Hersey S, 35:277–305
Hidaka H, 32:377–97
Hieble JP, 33:243–79
Hinson JA, 32:471–510
Hitchings GH, 32:1–6
Hollister LE, 33:165–77
Holsapple MP, 36:131–59
Homeister JW, 34:17–40
Howd R, 35:341–68
Howlett AC, 35:607–34
Hoyer PB, 36:307–31
Hsia SMT, 34:41–67
Hsieh L-L, 34:41–67
Huff J, 34:343–72; 36:573–96
Hulbert WC, 32:109–34

J

Jordan VC, 35:195–211

K

Kalkbrenner F, 36:429–59
Kaminski NE, 36:131–59
Karras JG, 36:131–59
Kjelsberg MA, 32:167–83
Kobayashi R, 32:377–97
Kopin IJ, 33:467–95
Korzekwa KR, 35:369–90
Krueger KE, 32:211–37

L

Lai J, 36:379–401
Lake BG, 35:483–507
Laskin DL, 35:655–77
Lassègue B, 36:281–306
Lazo JS, 35:635–53
Ledbetter JA, 36:131–59
Lee HJ, 34:321–41
Lefer AM, 33:71–90
Lefer DJ, 33:71–90
Lefkowitz RJ, 32:167–83
Lester HA, 34:219–49
Lewis JL, 33:383–407
Li B, 32:579–621
Li C, 36:185–201
Liehr JG, 36:203–32
Liu LF, 34:191–218
Llinás R, 32:399–421
Lowenthal DT, 32:271–302
Lucchesi BR, 34:17–40
Lucier G, 34:343–72
Ludden T, 32:185–209
Lukas SE, 36:333–57

M

Macdonald RL, 35:463–82
Madden KS, 35:417–48
Mager S, 34:219–49
Marton LJ, 35:55–91
Masaki T, 35:235–55
Maxwell MJ, 35:129–44
Miljanich GP, 35:707–34
Minneman KP, 34:117–33
Mirsalis JC, 35:145–64
Moal ML, 36:359–78
Mocchetti I, 32:301–26
Mohanraj D, 32:579–621
Mombouli J-V, 35:679–705
Monforte JA, 35:125–44
Mrozik H, 32:537–53
Mulder GJ, 32:25–49
Murray MD, 33:435–65
Myers MG Jr, 36:615–58

N

Neal RA, 36:35–46
Nicholas RA, 35:541–79
Nichols AJ, 33:243–79
Nicotera P, 32:449–70

O

Oguri K, 34:251–79
Olah ME, 35:581–606
Oliyai R, 33:521–44
Olson M, 32:579–621
Ondetti MA, 34:1–16
Ostrowski J, 32:167–83

P

Pang S, 32:623–69
Papadopoulos V, 32:211–37
Pechnick RN, 33:353–82
Pegg AE, 35:55–91
Pendino KJ, 35:655–77
Peoples RW, 36:185–201
Pettit DL, 36:659–701
Piazza PV, 36:359–78
Pitt BR, 35:635–53
Polson JB, 36:403–27
Porreca F, 36:379–401
Portoghese PS, 32:239–69

Q

Quick MW, 34:219–49

R

Radić Z, 34:281–320
Ramachandran J, 35:707–34
Ramakrishnan S, 32:579–621
Rand MJ, 33:24–44
Regunathan S, 36:511–44
Reiffenstein RJ, 32:109–34
Reinberg AE, 32:51–66
Reis DJ, 33:309–52; 36:511–44
Ricaurte GA, 33:639–77
Richman DD, 33:149–64
Robbins A, 36:47–81
Roberts DW, 32:471–510
Rock DM, 35:463–82
Rockhold RW, 33:497–520
Roth SH, 32:109–34
Ruffolo RR Jr, 33:243–79

S

Sabol KE, 33:639–77
Sachs G, 35:277–305
Sanders VM, 35:417–48
Scarpace PJ, 32:271–99
Schatz AR, 36:131–59
Schieven GL, 36:131–59
Schultz G, 36:429–59
Schweizer FE, 36:659–701
Seiden LS, 33:639–77
Sheiner LB, 32:185–209
Shin JM, 35:277–305
Simonian NA, 36:83–106
Sipes IG, 36:307–31
Smith RD, 32:135–65
Smits JFM, 35:501–39
Snyder SH, 35:213–33
Spitz IM, 36:47–81
St-Pierre MV, 32:623–69
Stadel J M, 33:243–79
Stanski D, 32:423–47
Stella VJ, 33:521–44
Stiles GL, 35:581–606
Strada SJ, 36:403–27
Struijker-Boudier HAJ, 35:509–39
Sunahara RK, 36:461–80

T

Takemori AE, 32:239–69
Taylor P, 34:281–320
Thomas HA, 33:91–108
Timmermans PBMWM, 32:135–65
Tolstoshev P, 33:573–96
Tritscher A, 34:343–72
Tumer N, 32:271–99

U

Urban L, 36:253–80

V

Vanderah TW, 36:379–401
Vanhoutte PM, 35:679–705

W

Wagner JA, 35:257–76
Wahlestedt C, 33:309–52
Wallmark B, 35:277–305
Wang CC, 35:93–127
Wei ET, 33:91–108
Weight FF, 36:185–201
Weissmann G, 35:449–62
Weston AH, 33:597–637
White MF, 36:615–58
Winegar RA, 35:145–64
Wolff MS, 36:573–96
Wong PC, 32:135–65
Woosley RL, 36:233–52

X

Xu X, 32:623–69

Y

Yager JD, 36:203–32
Yamada H, 34:251–79
Yamane HK, 33:201–41
Yoshimura H, 34:251–79

Z

Zaki PA, 36:379–401
Zhang J, 35:213–33
Ziegler DM, 33:179–99

CHAPTER TITLES, VOLUMES 32–36

PREFATORY CHAPTERS

Antagonists of Nucleic Acid Derivatives as Medicinal Agents	GH Hitchings	32:1–6
The Quest for a Cure	GB Elion	33:1–23
Adventures in Autopharmacology: A Biographic View with Digressions into Other Matters	MJ Rand	33:24–44
From Peptides to Peptidases: A Chronicle of Drug Discovery	MA Ondetti	34:1–16
A Research Trail Over Half A Century	RF Furchgott	35:1–27
A Personal View of Pharmacology	J Black	36:1–33
A Career in Toxicology	RA Neal	36:35–46

ALLERGY AND DRUG SENSITIVITY

Catecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness	KS Madden, VM Sanders, DL Felten	35:417–48

ANESTHETICS, ANALGESICS, & ANTIINFLAMMATORY AGENTS

Pharmacokinetics and Pharmacodynamics of Anesthetics	D Stanski	32:423–47
Antiinflammatory Peptide Agonists	ET Wei, HA Thomas	33:91–108
Targets for Antiinflammatory Drugs	BN Cronstein, G Weissmann	35:449–62

ANTIMICROBIAL, ANTIVIRAL, AND ANTIPARASITIC CHEMOTHERAPY

The Chemistry and Pharmacology of Avermectins	H Mrozik, MH Fisher	32:537–53
Polyamines as Targets for Therapeutic Intervention	LJ Marton, AE Pegg	35:55–91
Molecular Mechanisms and Therapeutic Approaches to the Treatment of African Trypanosomiasis	CC Wang	35:93–127
Progress in Antisense Oligonucleotide Therapeutics	ST Crooke, CF Bennett	36:107–29
Structural Mechanisms of HIV Drug Resistance	JW Erickson, SK Burt	36:545–71

AUTONOMIC PHARMACOLOGY

Inhaled Toxicants and Airway Hyperresponsiveness	JM Farley	32:67–88
Pharmacologic and Therapeutic Application of α_2-Adrenoceptor Subtypes	RR Ruffolo Jr, AJ Nichols, JM Stadel, JP Hieble	33:243–79
α_1-Adrenergic Receptor Subtypes	KP Minneman, TA Esbenshade	34:117–33

BEHAVIORAL AND PSYCHOPHARMACOLOGY

Geriatric Pharmacology: Basic and Clinical Considerations	DT Lowenthal, PJ Scarpace, N Tumer	32:271–302
New Antidepressants	LE Hollister, JL Claghorn	33:165–77
Cardiovascular Toxicity of Anabolic Steroids	RW Rockhold	33:497–520
Relationships Between Lead-Induced Learning Impairments and Changes in Dopaminergic, Cholinergic, and Glutamatergic Neurotransmitter System Functions	DA Cory-Slechta	35:391–415

CNS Effects and Abuse Liability of Anabolic-Androgenic Steroids	SE Lukas	36:333–57
Pathophysiological Basis of Vulnerability to Drug Abuse: Role of an Interaction Between Stress, Glucocorticoids and Dopaminergic Neurons	PV Piazza, ML Moal	36:359–78
CANCER, CHEMOTHERAPY, AND IMMUNOPHARMACOLOGY		
HIV Drug Resistance	DD Richman	33:149–64
DNA Topoisomerases: Essential Enzymes and Lethal Targets	AY Chen, LF Liu	34:191–218
The ARYL Hydrocarbon Receptor Complex	Oliver Hankinson	35:307–40
Metallothionens and Cell Death by Anticancer Drugs	JS Lazo, BR Pitt	35:635–53
Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers	MP Holsapple, JG Karras, JA Ledbetter, GL Schieven, SW Burchiel, DR Davila, AR Schatz, NE Kaminski	36:131–59
CARDIOVASCULAR PHARMACOLOGY		
Pharmacology of Nonpeptide Angiotensin II Receptor Antagonists	P Timmermans, AT Chiu, PC Wong, WF Herblin, RD Smith	32:135–65
Pharmacology of the Endothelium in Ischemia-Reperfusion and Circulatory Shock	AM Lefer, DJ Lefer	33:71–90
Complement Activation and Inhibition in Myocardial Ischemia and Reperfusion Injury	JW Homeister, BR Lucchesi	34:17–40
Pharmacology of Cardiac and Vascular Remodeling	HAJ Struijker-Boudier, JFM Smits, JGR De Mey	35:509–39
Angiotensin Receptors and Their Therapeutic Implications	KK Griendling, B Lassègue, RW Alexander	36:281–306
CLINICAL TOXICOLOGY AND DRUG INTERACTIONS		
Cardiac Actions of Antihistamines	RL Woosley	36:233–52
DRUGS AND RESPIRATION		
ELECTROLYTES AND MINERAL METABOLISM		
Molecular Strategies for Therapy of Cystic Fibrosis	JA Wagner, AC Chao, P Gardner	35:257–76
ENDOCRINE PHARMACOLOGY		
Effects of Opioids on the Hypothalamo-Pituitary-Adrenal Axis	RN Pechnick	33:353–82
Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer	VC Jordan	35:195–211
Antiprogestins: Mechanism of Action and Contraceptive Potential	IM Spitz, HB Croxatto, A Robbins	36:47–81
Molecular Mechanisms of Estrogen Carcinogenesis	JD Yager, JG Liehr	36:203–32
Insulin Signal Transduction and the IRS Proteins	MG Myers Jr, MF White	36:615–58
ENVIRONMENTAL AND INDUSTRIAL PHARMACOLOGY AND TOXICOLOGY		
Hydrogen Sulphide and its Toxicologic Implications	RJ Reiffenstein, SH Roth, WC Hulbert	32:109–34
Respiratory Tract Uptake of Inhalants and Metabolism of Xenobiotics	AR Dahl, JL Lewis	33:383–407

Childhood Lead Poisoning and its Treatment	CR Angle	33:409–33
Carcinogenicity of TCDD: Experimental, Mechanistic, and Epidemiological Evidence	J Huff, G Lucier, A Tritscher	34:343–72
Risk Assessment of Environmental Chemicals	A Fan, R Howd, B Davis	35:341–68
Macrophages and Inflammatory Mediators in Tissue Injury	DL Laskin, KJ Pendino	35:655–77
Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings	MS Wolff, GW Collman, JC Barrett, J Huff	36:573–96
GASTROINTESTINAL PHARMACOLOGY		
The Pharmacology of the Gastric Acid Pump: The H^+,K^+ ATPase	G Sachs, JM Shin, C Briving, B Wallmark, S Hersey	35:277–305
MECHANISMS OF ACTION OF DRUGS AND CHEMICALS		
Mutagenesis of the Beta-2 Adrenergic Receptor: How Structure Elucidates Function	RJ Lefkowitz, J Ostrowski, MA Kjelsberg, MG Caron	32:167–83
Therapeutic Applications of Antisense Agents	ST Crooke	32:329–76
Pharmacology of Protein Kinase Inhibitors	H Hidaka, R Kobayashi	32:377–97
Calcium-Mediated Mechanisms in Chemically Induced Cell Death	S Orrenius, P Nicotera, G Bellomo	32:449–70
Role of Covalent and Noncolvalent Interactions in Cell Toxicity: Effects on Proteins	JA Hinson, DW Roberts	32:471–510
Cytotoxic Conjugates Containing Translational Inhibitory Proteins	S Ramakrishnan, D Fryxell, D Mohanraj, M Olson, B Li	32:579–621
Calmodulin in Neurotransmitter and Hormone Action	ME Gnegy	33:45–70
Covalent Modifications of G-Proteins	B-K Fung, HK Yamane	33:201–41
Gene Therapy: Concepts, Current Trials, and Future Directions	P Tolstoshev	33:573–96
Putative Mechanisms of Toxicity of 3-Methylindole: From Free Radical to Pneumotoxicosis	TM Bray, KS Emmerson	34:91–115
Mechanisms of Hepatocarcinogenicity of Peroxisome-Proliferating Drugs and Chemicals	BG Lake	35:483–507
P_2-Purinergic Receptors: Subtype-Associated Signaling Responses and Structure	TK Harden, JL Boyer, RA Nicholas	35:541–79
Pharmacology of Cannabinoid Receptors	AC Howlett	35:607–34
Diversity and Selectivity of Receptor–G Protein Interaction	T Gudermann, F Kalkbrenner, G Schultz	36:429–59
Complexity and Diversity of Mammalian Adenylyl Cyclases	RK Sunahara, CW Dessauer, AG Gilman	36:461–80
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins	JH Exton	36:481–509
METABOLIC FATE OF DRUGS AND CHEMICALS		
Glucuronidation and its Role in Regulation of Biological Activity of Drugs	GJ Mulder	32:25–49
Catalytic Sites of Hemoprotein Peroxidases	PRO de Montellano	32:89–107
Recent Studies on the Structure and Function of Multisubstrate Flavin-Containing Monooxygenases	DM Ziegler	33:179–99
Macromolecular Adducts: Biomarkers for Toxicity and Carcinogenesis	LW Chang, SMT Hsia, P-C Chan, L-L Hsieh	34:41–67
Regiochemistry of Cytochrome P450 Isozymes	K Oguri, H Yamada, H Yoshimura	34:251–79

Structural Basis of Selective Cytochrome P450 Inhibition	JR Halpert	35:29–53
Cytochromes P450 Expression Systems	FJ Gonzalez, KR Korzekwa	35:369–90
P-Glycoproteins and Multidrug Resistance	WT Bellamy	36:161–83

MISCELLANEOUS

Concepts in Chronopharmacology	AE Reinberg	32:51–66

NEUROMUSCULAR PHARMACOLOGY

NEUROPHARMACOLOGY AND NEUROCHEMISTRY

Mitochondrial Benzodiazopine Receptors and the Regulation of Steroid Biosynthesis	KE Krueger, V Papadopoulos	32:211–37
The Theoretical Basis for a Pharmacology of Nerve Growth Factor Biosynthesis	I Mocchetti	32:301–26
The Central Role of Voltage-Activated and Receptor-Operated Calcium Channels in Neuronal Cells	M Bertolino, R Llinás	32:399–421
$GABA_B$ Receptor Pharmacology	NG Bowery	33:109–47
Neuropeptide Y-Related Peptides and Their Receptors—Are the Receptors Potential Therapeutic Drug Targets?	C Wahlestedt, DJ Reis	33:309–52
β-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease	B Cordell	34:69–89
Permeation Properties of Neurotransmitter Transporters	HA Lester, S Mager, MW Quick, JL Corey	34:219–49
The Cholinesterases: From Genes to Proteins	P Taylor, Z Radić	34:281–320
Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition	JM Fukuto, G Chaudhuri	35:165–94
Nitric Oxide in the Nervous System	J Zhang, SH Snyder	35:213–33
Polyamine Regulation of *N*-Methyl-D-Aspartate Receptor Channels	RL Macdonald, DM Rock	35:463–82
Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation	ME Olah, GL Stiles	35:581–606
Oxidative Stress in Neurodegenerative Diseases	NA Simonian, JT Coyle	36:83–106
Lipid vs Protein Theories of Alcohol Action in the Nervous System	RW Peoples, C Li, FF Weight	36:185–201
New Pharmacological Strategies for Pain Relief	A Dray, L Urban	36:253–80
Opioid Receptor Types and Subtypes: The δ Receptor as a Model	PA Zaki, EJ Bilsky, TW Vanderah, J Lai, CJ Evans, F Porreca	36:379–401
Pharmacology of Nicotine: Addiction and Therapeutics	NL Benowitz	36:597–613
Imidazoline Receptors and Their Endogenous Ligands	S Regunathan, DJ Reis	36:511–44
Exocytosis: Proteins and Perturbations	GJ Augustine, ME Burns, WM DeBello, DL Pettit, FE Schweizer	36:659–701

PERINATAL AND DEVELOPMENTAL PHARMACOLOGY

PHARMACOKINETICS, DRUG ABSORPTION, AND EXCRETION

Population Pharmacokinetics/Dynamics	LB Sheiner, T Ludden	32:185–209
Determinants of Metabolite Disposition	S Pang, X Xu, MV St-Pierre	32:623–69
Absorption of Peptide and Peptidomimetic Drugs	GL Amidon, HJ Lee	34:321–41

PHARMACOLOGICALLY ACTIVE NATURAL SUBSTANCES

Mechanisms of Aflatoxin Carcinogenesis	DL Eaton, EP Gallagher	34:135–72
Antagonists of Neuronal Calcium Channels: Structure, Function, and Therapeutic Implications	GP Miljanich, J Ramachandran	35:707–34

RENAL PHARMACOLOGY		
Renal Toxicity of Non-Steroidal Anti-Inflammatory Drugs	MD Murray, DC Brater	33:435–65
REPRODUCTION AND FERTILITY		
Assessment of Follicle Destruction in Chemical-Induced Ovarian Toxicity	PB Hoyer, IG Sipes	36:307–31
SMOOTH MUSCLE PHARMACOLOGY		
Pharmacological Implications of the Flow-Dependence of Vascular Smooth Muscle Tone	JA Bevan, D Henrion	34:173–90
Possible Role of Endothelin in Endothelial Regulation of Vascular Tone	T Masaki	35:235–55
Kinins and Endothelial Control of Vascular Smooth Muscle	J-V Mombouli, PM Vanhoutte	35:679–705
Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle	JB Polson, SJ Strada	36:403–27
STRUCTURE-ACTIVITY RELATIONSHIPS AND MEDICINAL CHEMISTRY		
Selective Naltrexone-Derived Opioid Receptor Antagonists	AE Takemori, PS Portoghese	32:239–69
Biochemical and Molecular Pharmacology of Kinin Receptors	SG Farmer, RM Burch	32:511–36
Molecular Diversity of the Dopamine Receptors	O Civelli, JR Bunzow, DK Grandy	33:281–307
Pharmacology of Parkinson's Disease Therapy: An Update	IJ Kopin	33:467–95
Prodrugs of Peptides and Proteins for Improved Formulation and Delivery	R Oliyai, VJ Stella	33:521–44
Molecular and Ionic Mimicry of Toxic Metals	TW Clarkson	33:545–71
The Pharmacology of ATP-Sensitive Potassium Channels	G Edwards, AH Weston	33:597–637
Amphetamine: Effects on Catecholamine Systems and Behavior	LS Seiden, KE Sabol, GA Ricaurte	33:639–77
TECHNIQUES		
Tandem Mass Spectrometry: The Competitive Edge for Pharmacology	C Fenselau	32:555–78
An Evaluation of the Role of Calcium in Cell Injury	AW Harman, MJ Maxwell	35:129–44
Transgenic Animal Models for Detection of In Vivo Mutations	JC Mirsalis, JA Monforte, RA Winegar	35:145–64